Total Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 249 shares of the company’s stock, valued at approximately $206,000.
A number of other institutional investors and hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Finally, O Brien Wealth Partners LLC grew its position in Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
Analysts Set New Price Targets
Several analysts have issued reports on LLY shares. Guggenheim increased their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.56.
Eli Lilly and Company Stock Up 0.7%
LLY stock opened at $767.75 on Tuesday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $727.63 billion, a P/E ratio of 62.47, a PEG ratio of 1.08 and a beta of 0.44. The firm has a 50 day simple moving average of $776.59 and a 200-day simple moving average of $800.81.
Eli Lilly and Company Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is currently 48.82%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Analysts Make a Quantum Bet on D-Wave’s Cryogenic Packaging
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Traders Turn Bullish on Housing Stocks Again—3 Leading the Way
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Onsemi’s August Pullback Is a Signal to Buy for Tech Investors
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.